Physician profile
Jon E Welch
NPI 1639285034
$15,538.64
in general payments reported to CMS, 2019-2025
38 companies · $3,076 in 2025
The $3,076 reported for 2025 was more than what 79% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $1,694 · 2021: $1,922 · 2022: $2,214 · 2023: $2,382 · 2024: $2,721 · 2025: $3,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,064 · Consulting Fee: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,064.40 |
| Consulting Fee | $114.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,918.68 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,780.87 | 2019-2025 | Airsupra, Tezspire, Brilinta |
| Genzyme Corporation | $1,708.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,663.51 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $1,414.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novartis Pharmaceuticals Corporation | $765.83 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $756.18 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $693.18 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $689.19 | 2019-2023 | Cutaquig |
| Pfizer INC. | $615.11 | 2019-2025 | |
| Kaleo, INC. | $529.59 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $481.87 | 2020-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $274.18 | 2019-2022 | |
| Grifols USA, LLC | $257.63 | 2019-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $212.92 | 2019-2025 | Dupixent |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.